Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
Artikel i vetenskaplig tidskrift, 2019

© 2019, The Author(s). Introduction: The effects of the GLP-1 analogue liraglutide on time in hypoglycaemia, time in hyperglycaemia, and time in range for type 2 diabetes patients initially treated with multiple daily insulin injections (MDI) were investigated. Variables associated with hypoglycaemia in the current population were also identified. Methods: Analyses were based on data from a previously performed double-blind, placebo-controlled trial in which 124 MDI-treated patients with type 2 diabetes were randomized to liraglutide or placebo. Masked continuous glucose monitoring (CGM) was performed at baseline and week 24 in 99 participants. Results: The mean time in hypoglycaemia was similar for participants receiving liraglutide and those receiving placebo after 24 weeks of treatment. Mean time in target was greater in the liraglutide group than in the placebo group: 430 versus 244 min/24 h (p < 0.001) and 960 versus 695 min/24 h (p < 0.001) for the two glycaemic ranges considered, 4–7 mmol/l and 4–10 mmol/l, respectively. Mean time in hyperglycaemia was lower in the liraglutide group: 457 versus 723 min/24 h (p = 0.001) and 134 versus 264 min/24 h (p = 0.023) for the two cutoffs considered, > 10 mmol/l and > 14 mmol/l, respectively. Lower mean glucose level, lower C-peptide, and higher glucose variability were associated with an increased risk of hypoglycaemia in both treatment groups. Higher proinsulin level was associated with a lower risk of hypoglycaemia in the liraglutide group. Conclusion: For type 2 diabetes patients initially treated with MDI, introducing liraglutide had a beneficial effect on glucose profiles estimated by masked CGM. Mean glucose level, glycaemic variability, C-peptide, and proinsulin level influenced the risk of hypoglycaemia in this population. Trial Registration: ClinicalTrials.gov, number (EudraCT nr: 2012-001941-42). Funding: Novo Nordisk funded this study. The Diabetes Research Unit, NU-Hospital Group funded the journal’s Rapid Service Fee.

Placebo

Continuous glucose monitoring

Hyperglycaemia

Hypoglycaemia

Liraglutide

Randomized clinical trial

Time in range

Type 2 diabetes mellitus

Författare

Sheyda Sofizadeh

Göteborgs universitet

NU-sjukvården

Henrik Imberg

Statistiska Konsultgruppen

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Arndís F. Ólafsdóttir

NU-sjukvården

Göteborgs universitet

Magnus Ekelund

Novo Nordisk

Lunds universitet

S. Dahlqvist

Göteborgs universitet

NU-sjukvården

Irl B. Hirsch

University of Washington

Karin Filipsson

Lunds universitet

Bo Ahrén

Lunds universitet

Stefan Sjöberg

Karolinska universitetssjukhuset

Jaako Tuomilehto

King Abdulaziz University

National Institute for Health and Welfare

Helsingin Yliopisto

Marcus Lind

Göteborgs universitet

NU-sjukvården

Diabetes Therapy

1869-6953 (ISSN) 1869-6961 (eISSN)

Ämneskategorier

Endokrinologi och diabetes

Annan klinisk medicin

Allmänmedicin

DOI

10.1007/s13300-019-00692-1

Mer information

Senast uppdaterat

2020-11-13